v3.22.4
Collaboration, Licensing and Other Arrangements - Schedule of Revised Anticipated Cash Flows from Transactions Allocated Performance Obligations (Detail) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 31, 2021
Oct. 16, 2021
Aug. 12, 2021
Apr. 30, 2022
Dec. 31, 2022
Aug. 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation $ 50,900,000          
R&D Services and License | Over Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation [1] $ 18,400,000          
Progress Measure Ratably          
Recognition Period [2] May 2021 - Oct 2021          
Next-Gen R&D Services | Over Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation [1] $ 7,200,000          
Progress Measure Input          
Recognition Period [3] % of completion of costs          
Collaboration and License Agreement | Tyvaso DPI            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total anticipated cash flows     $ 221,500,000     $ 221,500,000
Collaboration and License Agreement | Tyvaso DPI | R&D Services and License | Over Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation [1],[4]     $ 6,000,000.0      
Progress Measure [4]     Ratably      
Recognition Period [2],[4]     Aug 2021 - Oct 2021      
Collaboration and License Agreement | Tyvaso DPI | Next-Gen R&D Services | Over Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation [1]     $ 8,800,000      
Progress Measure     Input      
Recognition Period [5]     % of completion of costs      
Collaboration and License Agreement | Tyvaso DPI | Manufacturing Services | Point In Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation [1]     $ 206,700,000      
Recognition Period [6]     Transfer of control      
Collaboration and License Agreement | United Therapeutics Corporation            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Total anticipated cash flows [7]   $ 463,500,000   $ 483,200,000 $ 722,300,000  
Anticipated Revenue Allocation         $ 50,900,000  
Collaboration and License Agreement | United Therapeutics Corporation | R&D Services and License | Over Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Progress Measure [8]   Ratably   Ratably Ratably  
Recognition Period [8],[9]   Aug 2021 - Oct 2021   Aug 2021 - Oct 2021 Aug 2021 - Oct 2021  
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Over Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation [1],[10]   $ 4,800,000   $ 5,900,000 $ 10,000,000.0  
Progress Measure [10]   Input   Input Input  
Recognition Period [5],[10]   % of completion of costs   % of completion of costs % of completion of costs  
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Point In Time            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Anticipated Revenue Allocation [1]   $ 458,700,000 [11]   $ 477,200 $ 712,300  
Recognition Period   Transfer of control [11],[12]   Transfer of control Transfer of control  
[1]

Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.
[2]

Represents the estimated period when the R&D Services performance obligation will be substantially complete.
[3]

Pre-Commercial Services and Next-Gen R&D Services performance obligations will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.
[4] The license for the Company’s IP was considered to be interdependent with the development activities to support approval of Tyvaso DPI. A sales-based royalty is promised in exchange for the IP license; therefore, the royalties associated with the license are excluded from the determination of the transaction price and the Company will recognize revenue as the sale of Tyvaso DPI to a patient occurs.
[5]

The Next-Gen R&D Services performance obligation will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.
[6]

The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to the customer; therefore, no revenue associated with this obligation was recognized during the year ended December 31, 2021. The allocation of transaction price includes a material right related to manufacturing services. The total anticipated cash flow is based on the Company’s estimated production and the ultimate cash flows may vary as manufacturing purchase orders are received.
[7]

The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.
[8]

The license for the Company’s IP was considered to be interdependent with the development activities to support approval of Tyvaso DPI. A sales-based royalty is promised in exchange for the IP license; therefore, the royalties associated with the license are excluded from the determination of the transaction price and the Company will recognize revenue as the sale of Tyvaso DPI to a patient occurs.

[9]

Represents the period when the revenue for the R&D Services performance obligation was recognized.
[10]

The standalone selling price (“SSP”) for the Next-Gen R&D Services performance obligation was based on industry ratios as well as the Company’s historical R&D projects. The transaction price for the Next-Gen R&D Services was based on fixed consideration which was allocated between performance obligations as discussed in note (2) above.
[11]

Pre-production activities under the CSA, such as facility expansion services and certain other administrative services, were considered bundled services that are part of the Company’s Manufacturing Services performance obligation, given the nature of the Company’s contractual responsibilities and ASC 606 requirements.
[12] The Manufacturing Services performance obligation will be recognized as control of manufactured products is transferred to the customer. The modification did not result in a cumulative catch-up adjustment as a result of the revenue being deferred for the performance obligations that were affected by the modification. The allocation of the transaction price for the Manufacturing Services includes a material right related to the Company’s estimated production of product in the amount of $144.5 million. The Company will sell product to UT under individual purchase orders, which represent distinct performance obligations. The total anticipated cash flow is based on the Company’s estimated production and the ultimate cash flows may vary as manufacturing purchase orders are received.